Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?
Author:
Funder
GlaxoSmithKline
Publisher
Elsevier BV
Subject
Cancer Research
Reference220 articles.
1. Imatinib in Philadelphia chromosome-positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome;Le Coutre;Am. J. Hematol.,2003
2. Definition of Biomarker - NCI Dictionary of Cancer terms - National Cancer institute [Internet],2021
3. EGFR mutations in lung, cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004
4. The emerging treatment landscape of targeted therapy in non- small-cell lung cancer;Yuan;Signal Transduct. Target. Ther.,2019
5. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy;Eroglu;Ther. Adv. Med. Oncol.,2016
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer;Frontiers in Oncology;2024-07-29
2. Artificial intelligence in ovarian cancer drug resistance advanced 3PM approach: subtype classification and prognostic modeling;EPMA Journal;2024-07-13
3. Predictive Value of Machine Learning for Platinum Chemotherapy Responses in Ovarian Cancer: Systematic Review and Meta-Analysis;Journal of Medical Internet Research;2024-01-22
4. Predictive Value of Machine Learning for Platinum Chemotherapy Responses in Ovarian Cancer: Systematic Review and Meta-Analysis (Preprint);2023-04-26
5. Lesion-specific 3D-printed moulds for image-guided tissue multi-sampling of ovarian tumours: A prospective pilot study;Frontiers in Oncology;2023-02-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3